Advertisement
BMY or MRK or NVS
BMY in downward trend: 10-day moving average moved below 50-day moving average on September 21, 2026
The 10-day moving average for BMY crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BMY moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for BMY entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Oscillator exited the oversold zone, 16 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 59 cases where BMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.848) is normal, around the industry mean (19.199). P/E Ratio (14.070) is within average values for comparable stocks, (34.793). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.039) settles around the average of (0.025) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
MRK in -2.49% downward trend, sliding for three consecutive days on October 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MRK declined for three days, in 139 of 271 cases, the price declined further within the following month. The odds of a continued downward trend are 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MRK as a result. In 47 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
MRK moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 193 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.749) is normal, around the industry mean (19.199). MRK's P/E Ratio (118.952) is considerably higher than the industry average of (34.793). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.025) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NVS's RSI Oscillator ascends from oversold territory
The RSI Indicator for NVS moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 15 of the 24 cases the stock moved higher. This puts the odds of a move higher at 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 44 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for NVS just turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 28 of 46 cases over the following month. The odds of a continued upward trend are 61%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 182 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.720) is normal, around the industry mean (19.199). P/E Ratio (22.187) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). Dividend Yield (0.032) settles around the average of (0.025) among similar stocks. P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
BMY | MRK | NVS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 74 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 11 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 76 | 29 | 7 | |
SMR RATING 1..100 | 22 | 79 | 33 | |
PRICE GROWTH RATING 1..100 | 46 | 9 | 46 | |
P/E GROWTH RATING 1..100 | 65 | 2 | 21 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (4) in the Pharmaceuticals Major industry is in the same range as MRK (11) and is somewhat better than the same rating for BMY (42). This means that NVS's stock grew similarly to MRK’s and somewhat faster than BMY’s over the last 12 months.
NVS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is in the same range as MRK (29) and is significantly better than the same rating for BMY (76). This means that NVS's stock grew similarly to MRK’s and significantly faster than BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is in the same range as NVS (33) and is somewhat better than the same rating for MRK (79). This means that BMY's stock grew similarly to NVS’s and somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (46) and is somewhat better than the same rating for NVS (46). This means that MRK's stock grew somewhat faster than BMY’s and somewhat faster than NVS’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is in the same range as NVS (21) and is somewhat better than the same rating for BMY (65). This means that MRK's stock grew similarly to NVS’s and somewhat faster than BMY’s over the last 12 months.
| BMY | MRK | NVS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 53% | N/A | 2 days ago 63% |
| Stochastic ODDS (%) | 1 day ago 53% | 1 day ago 63% | 1 day ago 44% |
| Momentum ODDS (%) | N/A | 1 day ago 56% | 1 day ago 54% |
| MACD ODDS (%) | N/A | N/A | 1 day ago 61% |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 57% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 57% | 1 day ago 51% |
| Advances ODDS (%) | 1 day ago 56% | 9 days ago 57% | 1 day ago 54% |
| Declines ODDS (%) | 3 days ago 54% | 3 days ago 51% | 10 days ago 45% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 63% | 1 day ago 35% |
| Aroon ODDS (%) | 1 day ago 54% | N/A | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while MRK’s FA Score has 4 green FA rating(s), and NVS’s FA Score reflects 4 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- MRK’s FA Score: 4 green, 1 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 5 bullish TA indicator(s), and NVS’s TA Score reflects 5 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 4 bearish.
- MRK’s TA Score: 5 bullish, 2 bearish.
- NVS’s TA Score: 5 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +1.66% price change this week, while MRK (@Pharmaceuticals: Major) price change was +1.97% , and NVS (@Pharmaceuticals: Major) price fluctuated +5.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.02%. For the same industry, the average monthly price growth was -4.09%, and the average quarterly price growth was +3.67%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
MRK is expected to report earnings on Oct 29, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.02% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with JNJ. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then JNJ could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | -1.48% | ||
| JNJ - MRK | 50% Loosely correlated | -0.25% | ||
| GSK - MRK | 50% Loosely correlated | +2.40% | ||
| AMGN - MRK | 47% Loosely correlated | +1.86% | ||
| NVS - MRK | 47% Loosely correlated | +2.38% | ||
| BIIB - MRK | 46% Loosely correlated | +1.08% | ||
More | ||||
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.